International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide
International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy that accompanies the destruction of the viable human embryo. Additionally, the company works with subsidiaries Lifeline Skin Technology and Lifeline Skin Care in the area of skin rejuvenation on a product that contains a nano-compound that facilitates the replenishment of the skin’s texture and elasticity.
Evidence of the company’s resolve to be a leader in the field of restorative medicine can be found in a recent partnership with The Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement calls for the team to launch Phase I/IIa clinical trials research on the effects of human parthenogenetic stem cells in people with Parkinson’s disease.
The credibility The Florey Institute brings to ISCO’s mission to build shareholder value cannot be understated. The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers, employing a staff of over 500. The center’s scientists comprise the largest neuroscience research team in Australia. Its work is conducted on a range of serious diseases, including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and addiction. Further, The Florey is viewed by many as a world leader in imaging technology, stroke rehabilitation and epidemiological studies.
The company’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine aiding in the study of prostate disease, human renal and bladder diseases, human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. ISCO markets and sells skincare products through its website, channel sales, distributors and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corp. was founded in 2001 and is headquartered in Carlsbad, California.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
International Stem Cell Corp. (OTCQB: ISCO) builds shareholder value through the development of restorative medicine using stem cell technology. Through its innovative parthenogenesis technology, the company makes use of human stem cells from unfertilized oocytes (eggs), bypassing common ethical controversy that accompanies the destruction of the viable human embryo. Additionally, the company works with subsidiaries Lifeline Skin Technology and Lifeline Skin Care in the area of skin rejuvenation on a product that contains a nano-compound that facilitates the replenishment of the skin’s texture and elasticity.
Evidence of the company’s resolve to be a leader in the field of restorative medicine can be found in a recent partnership with The Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement calls for the team to launch Phase I/IIa clinical trials research on the effects of human parthenogenetic stem cells in people with Parkinson’s disease.
The credibility The Florey Institute brings to ISCO’s mission to build shareholder value cannot be understated. The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers, employing a staff of over 500. The center’s scientists comprise the largest neuroscience research team in Australia. Its work is conducted on a range of serious diseases, including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, traumatic brain and spinal cord injury, depression, multiple sclerosis, Huntington’s disease, motor neuron disease, schizophrenia, mental illness and addiction. Further, The Florey is viewed by many as a world leader in imaging technology, stroke rehabilitation and epidemiological studies.
The company’s human cell culture products are made up of adult stem cells and reagents for regenerative medicine aiding in the study of prostate disease, human renal and bladder diseases, human corneal cells present in corneal disease and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. ISCO markets and sells skincare products through its website, channel sales, distributors and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corp. was founded in 2001 and is headquartered in Carlsbad, California.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
